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AbstrACt
Objectives To compare efficacy/safety of oral tramadol 
75 mg/dexketoprofen 25 mg (TRAM/DKP) and TRAM 75 mg/
paracetamol 650 mg (TRAM/paracetamol) in moderate to 
severe pain following surgical removal of impacted lower 
third molar.
Design Multicentre, randomised, double-blind, placebo-
controlled, phase IIIb study.
Participants Healthy adult patients scheduled for surgical 
extraction of at least one fully/partially impacted lower 
third molar requiring bone manipulation. 654 patients were 
randomised and 653 were eligible for analysis.
Interventions Surgery was performed under local 
anaesthetic. No sedation was permitted. Patients 
rated pain intensity (PI) using an 11-Numerical Rating 
Scale (NRS) (0 no pain; 10 worst pain). Participants 
experiencing moderate/severe pain (≥4) within 4 hours 
of surgery were randomised (2:2:1 ratio) to a single 
oral dose of TRAM/DKP 75/25 mg, TRAM/paracetamol 
75/650 mg or placebo.
Main outcome measures Efficacy was based patients’ 
electronic diaries. Analgesia and pain were recorded as 
follows: pain relief (PAR) on a 5-point Verbal Rating Scale 
(0=‘no relief’, 1=‘a little (perceptible) relief’, 2=‘some 
(meaningful) relief’, 3=‘lot of relief’, 4=‘complete relief’) 
at the predefined postdose time points t15 min, t30 min, 
t1 hour, t1.5 hour, t2 hour, t4 hour, t6 hour and t8 hour and 
PI on the 11-point NRS at t0 and at the same predefined 
postdose time points. Onset of analgesia documented 
using double stopwatch method over a 2-hour period. 
Primary endpoint was total pain relief over 6 hours 
(TOTPAR6). Rescue medication was available during the 
treatment period.
results TRAM/DKP was superior to TRAM/paracetamol 
and placebo at the primary endpoint TOTPAR6 (p<0.0001). 
Mean (SD) TOTPAR6 in the TRAM/DKP group was 13 
(6.97), while those in the active control and placebo groups 
were 9.1 (7.65) and 1.9 (3.89), respectively. Superiority 
of TRAM/DKP over active comparator and placebo was 
observed at all secondary endpoints. Incidence of adverse 
events was comparable between active groups.
Conclusions TRAM/DKP (75/25 mg) is effective and 
superior to TRAM/paracetamol (75/650 mg) in relieving 
moderate to severe acute pain following surgical removal 
of impacted lower third molar, with a faster onset of action, 
greater and durable analgesia, together with a favourable 
safety profile.
trial registration number EudraCT 2015-004152-22 and 
NCT02777970.
strengths and limitations of this study
 ► The main strength of this study is that with nearly 
800 patients screened, it is one of the largest to be 
carried out in patients with moderate to severe acute 
pain in the impacted third molar extraction model.
 ► The rigorous study design—multicentre, ran-
domised, double-blind, placebo-controlled, phase 
IIIb—coupled with the large patient cohort means 
that the quality of the evidence is high.
 ► This is a unique head-to-head study of tramadol/
dexketoprofen against tramadol/paracetamol an 
established combination rather than just a place-
bo-controlled study.
 ► The results show that tramadol hydrochloride/dex-
ketoprofen 75/25 mg oral fixed combination is ef-
fective and superior over tramadol hydrochloride/
paracetamol 75/650 mg in relieving moderate to 
severe acute pain following surgical removal of im-
pacted lower third molar.
 ► One of the limitations of this study is as this was a 
single-dose study that assessed the short-term an-
algesic efficacy of tramadol/dexketoprofen in com-
parison with tramadol/paracetamol and this could 
be addressed in a future multidose study of longer 
duration.
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IntrODuCtIOn  
The majority of patients with moderate to severe acute 
postoperative pain report inadequate pain relief (PAR).1 
This is in spite of well-known and published negative 
impact of inadequate PAR on clinical outcomes such 
as time to functional recovery, postsurgical complica-
tions, pain chronification and quality of life. It is conse-
quently associated with increased healthcare costs.1–4 
Attaining adequate PAR with monotherapy is difficult 
and multimodal analgesia is now accepted as the corner-
stone of effective pain treatment. Combining analgesics 
with diverse mechanisms of action and potential syner-
gistic effects means that a wider spectrum of pain can be 
covered, and lower doses of single drug components can 
be administered, thus enhancing efficacy and minimising 
adverse events (AEs).5 
Dexketoprofen (DKP) is a well-known inhibitor of 
cyclooxygenase (COX-1 and COX-2) with proven anal-
gesic and anti-inflammatory efficacy in a wide spectrum of 
acute pain syndromes; it appears to be as effective as the 
double dose of the racemic ketoprofen, but with a faster 
onset of analgesia. Its fast onset of action and favourable 
pharmacokinetics profile are enhanced by its formulation 
as trometamol salt, which has an increased bioavailability 
compared with the free drug. The rapid dissolution and 
absorption, (tmax between 0.25 and 0.75 hour) ensure 
rapid PAR which is crucial for the effective management 
of acute pain.6–8 DKP’s efficacy is complemented by its 
favourable safety profile with clinical data showing an AE 
profile similar to that of the new generation NSAIDs.8
Tramadol (TRAM), a μ-opioid receptor agonist, norepi-
nephrine and serotonin reuptake inhibitor, is a central-
acting analgesic and also shows a peripheral and local 
analgesic effect.9 10 Its opioid and non-opioid mechanisms 
are thought to act synergistically on descending inhibi-
tory pathways in the central nervous system. TRAM’s 
Table 1 Patients by treatment group
Overall
TRAM/
DKP
TRAM/
paracetamol Placebo
Screened 
patients
792 – – 
Randomised 
patients
654 261* 262 131
Intention-to-treat 
population
653 260 262 131
Safety population 653 260 262 131
Per-protocol 
population
620 246 248 126
*One patient was enrolled and randomised but was excluded from 
all the analysis populations because younger than 18 years old.
TRAM/DKP, tramadol/dexketoprofen.
Figure 1 Participant flow chart of study. ITT population consisted of all patients randomised; safety population of all patients 
who received study drug; PP population of all patients of the ITT who did not experience relevant protocol deviation related to 
efficacy endpoints of primary interest. *One patient excluded from analysis being aged less than 18 years. ITT, intention to treat; 
PP, per protocol; TRAM/DKP, tramadol/dexketoprofen. 
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analgesic efficacy is complemented by a long duration of 
action (half-life around 6 hours) and by a safety profile 
that favours TRAM over other opioids.8
The doses of TRAM hydrochloride 75 mg plus DKP 
25 mg were selected as the optimal for a combination 
in a previous dose-finding study11; subsequent multi-
ple-dose clinical trials in well-established models of 
acute visceral and somatic pain12 confirmed the combi-
nation of TRAM hydrochloride 75 mg with DKP 25 mg 
(TRAM/DKP) as an effective analgesic for the control of 
moderate to severe acute pain.13–16 TRAM/DKP offers a 
number of important advantages including: proven effi-
cacy and tolerability with a 25% overall reduction in the 
opioid dosage, improved compliance, as well as a conve-
nient mode of administration. TRAM/DKP (75/25 mg) 
(film-coated tablet) has been registered and released for 
commercial use in Europe.17
Direct comparisons of newly released drugs with older 
agents are rarely performed in clinical trials, although this 
kind of evidence is valuable to improve appropriateness 
of pharmacotherapy in clinical practice.18 This lack of 
data can make it difficult for clinicians to determine the 
optimal therapeutic option.19 To provide a meaningful 
comparison of the analgesic capabilities of TRAM/DKP 
fixed combination versus oral TRAM hydrochloride 75 
mg/paracetamol 650 mg (TRAM/paracetamol), a head-
to-head clinical trial was necessary.
The present phase IIIb trial (Dexketoprofen Analgesic 
eVolution wIth tramaDol) was designed to compare the 
analgesic efficacy and safety of a single dose of the fixed 
oral combination TRAM/DKP (75/25 mg) versus TRAM/
paracetamol (75/650 mg) in postoperative moderate to 
severe pain following extraction of impacted lower third 
molars. The model has a proven record of assay sensitivity 
to compare efficacy, including onset of analgesic action, 
in head-to-head trials.11 20 21
MethODs
It was performed at 18 centres in five European coun-
tries (Hungary, Italy, Poland, Spain and UK) and was 
conducted in accordance with the principles of Good 
Clinical Practice and the Declaration of Helsinki. The 
clinical phase of the study started in April 2016 and was 
concluded in February 2017.
Patients
Healthy adult patients (>18 years of age) scheduled to 
undergo surgical extraction of at least one fully or partially 
impacted lower third molar requiring bone manipulation 
were included in the trial. Criteria for randomisation 
included postoperative pain of moderate to severe inten-
sity (Numerical Rating Scale, NRS ≥4) within a 4-hour 
time lapse after the completion of the surgery.
Pregnant or breastfeeding women or women of child-
bearing potential not using adequate contraception were 
excluded from the study. The following conditions did 
not permit participation in the study: known allergy or 
hypersensitivity to study treatments, rescue medication 
(RM) or any other NSAIDs except those permitted in the 
study protocol, opioids and acetyl salicylic acid; history 
of peptic ulcer, gastrointestinal disorders induced by 
NSAIDs or gastrointestinal bleeding; Crohn’s disease 
or ulcerative colitis; severe asthma; moderate to severe 
renal dysfunction; severe hepatic dysfunction or cardiac 
dysfunction; active bleeding or coagulation disorders; 
history of or current epilepsy; history of drug or alcohol 
abuse; as well as history/presence of any illness or condi-
tion that, in the opinion of the Investigator, might pose 
a risk to the patient or confound the efficacy and safety 
results of the study. Patients who had received any inves-
tigational drug or participated in any other clinical trials 
within the previous 4 weeks were also excluded. Patients 
who had taken, sedatives, hypnotic agents or analgesics 
within 12 hours before surgery and 8 hours postdose (or 
5 days prior to the surgery day in case of COX-2 inhib-
itors) were not considered eligible. Moreover, subjects 
under chronic opioid treatment, or using and not suitable 
for withdrawing, within 48 hours (or five half-lives, which-
ever the longer presurgery), drugs posing a risk to the 
patient and for 24 hours postdose, were also not enrolled. 
Table 2 Patient demographic and baseline characteristics 
by treatment group (ITT population)
Demographic 
and baseline 
characteristics
TRAM/
DKP, n=260
TRAM/
paracetamol, 
n=262
Placebo, 
n=131
Race (n, %)
  Asian 14 (5.4) 21 (8.0) 6 (4.6)
  Black or African 
American
7 (2.7) 3 (1.1) 6 (4.6)
  White 235 (90.4) 233 (88.9) 118 (90.1)
  Other 4 (1.5) 5 (1.9) 1 (0.8)
Gender (n, %)
  Female 152 (58.5) 158 (60.3) 78 (59.5)
  Male 108 (41.5) 104 (39.7) 53 (40.5)
Age (years)
  Mean (SD) 26.8 (7.48) 27.1 (8.13) 26.5 (7.67)
  Range 18–52 18–63 18–59
Body mass index
  Mean (SD) 23.5 (4.48) 23.4 (4.36) 23.7 (4.21)
  Range 16–44 15–44 16–40
Pain intensity (NRS-PI)
  Mean (SD) 5.7 (1.4) 5.5 (1.3) 5.6 (1.3)
  4≤ NRS-PI ≤6 
(n, %)
508 (77.8) 196 (75.4) 210 (80.2)
  NRS-PI >6  
(n, %)
144 (22.1) 63 (24.2) 52 (19.8)
4≤ NRS-PI ≤6 corresponding to moderate pain intensity; NRS-
PI >6 corresponding to severe pain intensity.
ITT, intention to treat; NRS, Numerical Rating Scale; TRAM/
DKP, tramadol/dexketoprofen.
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Lastly, patients were excluded if any surgical complication 
occurred that, in the opinion of the investigator, would 
interfere with the study procedures or assessments.
study design
This was a multicentre, randomised, double-blind, double-
dummy, parallel-group, placebo and active-controlled, 
single-dose, phase IIIb study including three treatment 
arms. Participation in the study lasted for approximately 
3 weeks for each patient and was made up of: a screening 
period, (within 2 weeks before randomisation), including 
the presurgery procedures to be completed at least 1 day 
prior to surgery and ending within the 4 hours qualifica-
tion postsurgery; randomisation and treatment admin-
istration (day 1, t0) followed by an 8-hour assessment 
period during which patients recorded efficacy data using 
an electronic diary (eDiary) both at site (up to t2 hour) 
and out of site (up to t8 hour); followed by an end of 
study visit (6±1 days after randomisation).
Surgery was performed under local anaesthetic using 2% 
lidocaine (with 1:80.000 epinephrine) up to a total volume 
of 5.4 mL per molar. No sedation was permitted. After 
surgery, patients rated pain intensity (PI) using an 11-NRS 
ranging from 0 (no pain) to 10 (worst pain).22 23 Partici-
pants experiencing moderate to severe pain (≥4) within 
4 hours after surgery were randomised with a 2:2:1 ratio to 
a single oral dose of TRAM/DKP 75/25 mg, TRAM/parac-
etamol 75/650 mg or placebo. The inclusion of a placebo 
group was deemed acceptable considering the self-limiting 
nature of postoperative dental pain, the short duration of 
the study, and the fact that an effective RM was provided to 
participants requesting additional PAR; this is in line with 
Table 3 Summary of descriptive statistics TOTPAR, % max TOTPAR SPID and % max SPID over 2, 4, 6 and 8 hours
Parameter Time points
TRAM/DKP n=260
TRAM/
paracetamol n=262 Placebo n=131
Statistical test
TRAM/DKP versus 
TRAM/paracetamol
Mean (SD) Mean (SD) Mean (SD) P value
TOTPAR 2 hours 4.6 (1.99) 3.3 (2.19) 0.8 (1.22) <0.0001 
4 hours 9.5 (4.47) 3.3 (2.19) 0.8 (1.22) <0.0001 
6 hours (primary endpoint) 13.0 (6.97) 6.5 (4.95) 1.5 (2.71) <0.0001 
8 hours 15.3 (9.22) 9.2 (7.65) 1.9 (3.89) <0.0001 
% max
TOTPAR
2 hours 51.5 (22.08) 36.7 (24.29) 9.1 (13.56) <0.0001
4 hours 56.1 (26.32) 38.1 (29.11) 8.8 (15.95) <0.0001
6 hours 51.9 (27.87) 36.6 (30.62) 7.7 (15.57) <0.0001
8 hours 46.5 (27.95) 34.2 (30.76) 7.1 (15.86) <0.0001
SPID 2 hours 6.4 (3.57) 4.1 (3.57) 0.3 (2.38) <0.0001
4 hours 13.6 (7.49) 8.2 (7.63) 1.1 (4.57) <0.0001
6 hours 18.4 (11.09) 11.7 (11.58) 1.6 (6.72) <0.0001
8 hours 21.5 (14.27) 14.4 (15.21) 2.2 (8.98) <0.0001
% max
SPID
2 hours 56.1 (27.31) 38.1 (32.05) 2.4 (23.06) <0.0001
4 hours 59.4 (29.03) 38.7 (34.87) 4.7 (21.93) <0.0001
6 hours 53.6 (30.14) 36.8 (35.27) 4.9 (21.58) <0.0001
8 hours 47.2 (29.62) 34.1 (34.89) 5.2 (21.48) <0.0001
Statistical test performed to compare active treatments only (ITT population).
ITT, intention to treat; SPID, sum of pain intensity difference; TOTPAR, total pain relief over 6 hours; TRAM/DKP, tramadol/dexketoprofen.
Figure 2 Mean TOTPAR at 6 hours (primary endpoint) and 
at 2, 4 and 8 hours for TRAM/DKP, TRAM/paracetamol and 
placebo with PAR was measured on a 5-point Verbal Rating 
Scale (0=‘no relief’ to 4=‘complete relief’). *Statistically 
significant comparison of TRAM/DKP versus TRAM/
paracetamol (p<0.0001). PAR, pain relief; TRAM/DKP, 
tramadol/dexketoprofen; TOTPAR6, total pain relief. 
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recent academic recommendations.24 RM consisted of oral 
ibuprofen (400 mg) and was permitted during the 8-hour 
postdose assessment period up to a maximum of two tablets 
at a minimum interval of 4 hours.
randomisation and masking
Randomisation was performed through Interac-
tive Voice/Web Response System according to a 
computer-generated randomisation sequence. Partic-
ipants, healthcare providers, medical monitors, other 
personnel involved in the conduction of the trial, 
data collectors and biometricians were unaware of the 
treatment that participants were receiving. Double-
blind conditions were ensured by the application of 
double dummy technique.
Figure 3 Time course of mean PAR over 8 hours for TRAM/DKP, TRAM/paracetamol and placebo with PAR measured on a 
5-point Verbal Rating Scale (0=‘no relief’ to 4=‘complete relief’). The area under the curve for pain relief at a given time point 
corresponds to TOTPAR at the same time point. *Statistically significant TRAM/paracetamol versus TRAM/DKP (p<0.0001); 
†Statistically significant TRAM/DKP versus TRAM/paracetamol (p<0.0006); ††Statistically significant TRAM/paracetamol versus 
TRAM/DKP (p<0.00086). PAR, pain relief; TRAM/DKP, tramadol/dexketoprofen; TOTPAR, total pain relief. 
Table 4 Percentage of responders to treatment over 2, 4, 6 and 8 hours (ITT population)
Time points Responder
TRAM/DKP
n=260, (%)
TRAM/paracetamol 
n=262, (%)
Placebo
n=131, (%)
Statistical test
TRAM/DKP versus 
TRAM/paracetamol (p 
value)
max TOTPAR ≥50%
  2 hours Yes 185 (71.2) 116 (44.3) 6 (4.6) <0.0001
No 75 (28.8) 146 (55.7) 125 (95.4)
  4 hours Yes 185 (71.2) 113 (43.1) 8 (6.1) <0.0001
No 75 (28.8) 149 (56.9) 123 (93.9)
  6 hours Yes 157 (60.4) 101 (38.5) 5 (3.8) <0.0001
No 103 (39.6) 161 (61.5) 126 (96.2)
  8 hours Yes 124 (47.7) 93 (35.5) 7 (5.3) 0.0047
No 136 (52.3) 169 (64.5) 124 (94.7)
PI reduction >30%
  2 hours Yes 231 (88.8) 166 (63.4) 21 (16.0) <0.0001
No 29 (11.2) 96 (36.6) 110 (84.0)
  4 hours Yes 203 (78.1) 141 (53.8) 16 (12.2) <0.0001
No 57 (21.9) 121 (46.2) 115 (87.8)
  6 hours Yes 146 (56.2) 115 (43.9) 11 (8.4) 0.0066
No 114 (43.8) 147 (56.1) 120 (91.6)
  8 hours Yes 104 (40.0) 93 (35.5) 13 (9.9) 0.2885
No 156 (60.0) 169 (64.5) 118 (90.1)
ITT, intention to treat; PI, pain intensity; TOTPAR, total pain relief over 6 hours; TRAM/DKP, tramadol/dexketoprofen. 
 o
n
 13 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023715 on 6 February 2019. Downloaded from 
6 Gay-Escoda C, et al. BMJ Open 2019;9:e023715. doi:10.1136/bmjopen-2018-023715
Open access 
Sample size calculation
A sample size of 230 patients per active arm was considered 
adequate to demonstrate the non-inferiority of TRAM/
DKP compared with TRAM/paracetamol assuming a 
non-inferiority margin of 20%, a power of 80% and an 
overall significance level of 2.5% (one sided). The mean 
total pain relief over 6 hours (TOTPAR6) for TRAM/
paracetamol is assumed equal to 7.4 (SD 6.30) based on 
a previously published trial.25 One hundred and fifteen 
patients in the placebo arm were considered sufficient to 
demonstrate the superiority of both TRAM/paracetamol 
and TRAM/DKP versus placebo for model sensitivity. 
Assuming about 10% of major protocol violators and 20% 
of screening failure rate a total of 640 patients needed 
to be randomised and 800 patients were expected to be 
screened.
efficacy evaluation
Evaluation of efficacy was based on data entered by 
patients in eDiary. Analgesia and pain were recorded by 
using the following measures: PAR on a 5-point Verbal 
Rating Scale (VRS) (0=‘no relief’, 1=‘a little (percep-
tible) relief’, 2=‘some (meaningful) relief’, 3=‘lot of 
relief’, 4=‘complete relief’)26 27 at the predefined post-
dose time points t15 min, t30 min, t1 hour, t1.5 hour, t2 
hour, t4 hour, t6 hour and t8 hour and PI on the 11-point 
NRS23 24 28 at t0 and at the same predefined postdose time 
points.
The onset of analgesia was documented using the 
double stopwatch method over a 2-hour period postdose. 
Following treatment, two stopwatches were automatically 
activated in the eDiary. Subjects were instructed to stop 
the first stopwatch when they felt ‘first perceptible’ PAR 
(FPPAR, ie, at the moment they first felt any PAR what-
soever) and the second when they experienced a ‘mean-
ingful’ PAR (MPAR, ie, when the relief from pain became 
meaningful to them). The FPPAR and MPAR could be 
alternatively defined by using the time point when PAR 
is assessed as 1 and 2, respectively, in case the stopwatch 
was not used or used after the recording of the PAR equal 
to 1 or 2. Furthermore, an overall assessment of the study 
medication was reported through patient global evalu-
ation (PGE) on a 5-point VRS (1=poor, 2=fair, 3=good, 
4=very good, 5=excellent) at the end of the 8-hour assess-
ment period or immediately before the RM intake.22 The 
time between treatment administration and first intake 
of RM, and percentage of patients requiring RM were 
also evaluated. After first intake of RM, patients were no 
longer required to use the eDiary, including the stop-
watch functionality.
Figure 4 Time course of mean PI over 8 hours for TRAM/DKP, TRAM/paracetamol and placebo with PI measured on 11-point 
Numerical Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst pain). *Statistically significant TRAM/DKP versus TRAM/
paracetamol (p<0.0001); †Statistically significant (p=0.0021); ††TRAM/paracetamol versus TRAM/DKP (p=0.0052). PI, pain 
intensity; TRAM/DKP, tramadol/dexketoprofen. 
Figure 5 Percentage of max TOTPAR at 2, 4, 6 and 8 hours 
for TRAM/DKP, TRAM/paracetamol and placebo with PAR 
measured on a 5-point Verbal Rating Scale (0=‘no relief’ 
to 4=‘complete relief’). *Statistically significant TRAM/DKP 
versus TRAM/paracetamol (p<0.0001). PAR, pain relief; 
TRAM/DKP, tramadol/dexketoprofen; TOTPAR, total pain 
relief.
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Primary and secondary endpoints
The primary efficacy endpoint was TOTPAR, calculated as 
the weighted sum of the PAR scores measured according 
to a 5-point VRS, over 6 hours postdose (TOTPAR6). 
Secondary efficacy endpoints included the time course of 
mean PAR and PI scores over 8 hours; TOTPAR over 2, 4 
and 8 hours postdose and the percentage of maximum 
calculated TOTPAR (% max TOTPAR) over 2, 4, 6 and 
8 hours; sum of pain intensity difference (SPID) and the 
percentage of maximum calculated SPID (% max SPID) 
over 2, 4, 6 and 8 hours; percentage of responders in terms 
of PAR or PI reduction, namely subjects who achieved at 
least 50% of max TOTPAR or at least 30% of PI reduc-
tion versus baseline at prespecified time points over the 
8 hours, respectively; time to FPPAR; time to confirmed 
FPPAR (ie, time to FPPAR if confirmed by experiencing 
MPAR) and time to MPAR; percentage of patients who 
achieved FPPAR, confirmed FPPAR and MPAR within 
30 min, 1 hour and 2 hours; PGE at 8 hours or whenever 
the patient used RM; time of first intake of RM since study 
drug intake; percentage of patients using RM at 2, 4, 6 or 
8 hours.
safety
Safety evaluation was based on the incidence, seri-
ousness, intensity and causal relationship of treat-
ment-emergent adverse events (TEAEs). AEs were 
assessed throughout the study. Safety was evaluated by 
the assessment of clinically significant changes post-
dose versus the baseline in the physical examination, 
vital signs (VSs; blood pressure and heart rate) and 
laboratory safety tests (haematology, biochemistry and 
urinalysis). Any patient who prematurely withdrew 
after having received study medication was encour-
aged to undergo the end of study visit.
statistical analysis
The primary efficacy variable was analysed on the per-pro-
tocol (PP) and intention-to-treat (ITT) populations to 
assess the non-inferiority hypothesis using analysis of 
covariance (ANCOVA) with one-sided significance level 
of 2.5% for testing the differences in treatment efficacy, 
as quantified by TOTPAR6, between TRAM/DKP and 
TRAM/paracetamol. The ANCOVA model included 
terms of treatment and the baseline PI (NRS) as covari-
ates. In case of non-inferiority being confirmed, the 
superiority of TRAM/DKP versus TRAM/paracetamol 
was tested on the ITT population. Superiority of TRAM/
DKP and TRAM/paracetamol versus placebo was evalu-
ated in order to confirm the model sensitivity on the ITT 
population. Non-inferiority hypothesis was satisfied if the 
lower limit of the CI for the estimated difference between 
TRAM/DKP and TRAM/paracetamol was greater than a 
non-inferiority margin of 20% of the estimated mean of 
TRAM/paracetamol.
Secondary efficacy analysis SPID6 was analysed for 
non-inferiority with the possibility to switch for supe-
riority analogously to the primary efficacy variable. All 
the other secondary efficacy variables were descrip-
tively analysed and tested for the superiority of TRAM/
DKP, when applicable, through ad hoc inferential anal-
yses, as follows: NRS-PI, SPID (excluded SPID6), %max 
SPID, TOTPAR (excluded TOTPAR6), %max TOTPAR 
(continuous variables) were analysed by ANCOVA model 
as for the primary efficacy variable or a repeated measure 
model if more than one value per patient; VRS-PAR and 
PGE (categorical variables) were analysed by Wilcoxon 
rank-sum test; percentage of patients who required RM, 
and percentage of patients achieving at least 50% max 
TOTPAR or 30% of PI reduction, with confirmed FPPAR 
or MPAR were tested using a χ2test. Time to use RM, time 
to FPPAR, confirmed FPPAR and MPAR were assessed 
using a log-rank test. All analyses were performed in SAS 
V.9.3 (SAS).
Imputation
The method of last observation carried forward was 
applied among patients who missed more than one 
consecutive data input; otherwise the missing value 
was replaced by the mean of the two non-missing data 
collected, respectively, before and after the missing one. 
Figure 6 Percentage of responder patient by treatment and 
time points. Response defined as at least 50% max TOTPAR 
or 30% PI reduction. *Statistically significant TRAM/DKP 
versus TRAM/paracetamol (p<0.01). PI, pain intensity; TRAM/
DKP, tramadol/dexketoprofen; TOTPAR, total pain relief. 
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This procedure was applied to all efficacy outcomes. If 
PI was missed at t0, the value recorded during qualifica-
tion procedure was used as a baseline. After RM intake, 
PI returned to its baseline (t0) level and PAR to zero (‘no 
relief’) for all subsequent time points (ie, baseline obser-
vation carried forward).
Figure 7 Percentage of patients achieving confirmed FPPAR within 30 min, 1 hour and 2 hours. TRAM/DKP versus TRAM/
paracetamol. *P<0.0001. FPPAR, first perceptible pain relief; TRAM/DKP, tramadol/dexketoprofen.
Table 5 Proportion of patients achieving FPPAR, confirmed FPPAR and MPAR at prespecified time interval of 30 min, 1 hour 
and 2 hours using stopwatch (ITT population)
Parameter Time interval Responder
TRAM/DKP 
n=260, (%)
TRAM/paracetamol 
n=262, (%)
Placebo n=131, 
(%)
Statistical test
TRAM/DKP versus 
TRAM/paracetamol 
(p value)
FPPAR 30 min Yes 207 (79.6) 184 (70.2) 66 (50.4) 0.0134
No 53 (20.4) 78 (29.8) 65 (49.6)
1 hour Yes 243 (93.5) 227 (86.6) 79 (60.3) 0.0093
No 17 (6.5) 35 (13.4) 52 (39.7)
2 hours Yes 247 (95.0) 231 (88.2) 80 (61.1) 0.0050
No 13 (5.0) 31 (11.8) 51 (38.9)
Confirmed 
FPPAR
30 min Yes 200 (76.9) 158 (60.3) 26 (19.8) <0.0001
No 60 (23.1) 104 (39.7) 105 (80.2)
1 hour Yes 234 (90.0) 190 (72.5) 32 (24.4) <0.0001
No 26 (10.0) 72 (27.5) 99 (75.6)
2 hours Yes 235 (90.4) 191 (72.9) 33 (25.2) <0.0001
No 25 (9.6) 71 (27.1) 98 (74.8)
MPAR 30 min Yes 99 (38.1) 71 (27.1) 6 (4.6) 0.0075
No 161 (61.9) 191 (72.9) 125 (95.4)
1 hour Yes 205 (78.8) 165 (63.0) 17 (13.0) <0.0001
No 55 (21.2) 97 (37.0) 114 (87.0)
2 hours Yes 235 (90.4) 191 (72.9) 33 (25.2) <0.0001
No 25 (9.6) 71 (27.1) 98 (74.8)
FPPAR, first perceptible pain relief; ITT, intention to treat; MPAR, meaningful pain relief; TRAM/DKP, tramadol/dexketoprofen. 
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Safety analysis
AEs were coded using the MedDRA dictionary. The inci-
dence of each TEAE was summarised by system organ 
class, preferred term and treatment. Clinically signifi-
cant abnormal findings in VS and physical examination 
were listed by treatment. Safety variables were anal-
ysed by descriptive statistics and were run on the safety 
population.
Definition of analysis population
The ITT population consisted of all patients randomised; 
safety population of all patients who received study drug; 
PP population of all patients of the ITT who did not 
experience relevant protocol deviation related to efficacy 
endpoints of primary interest.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved 
in developing plans for recruitment, design or imple-
mentation of the study. No patients were asked to advise 
on interpretation or writing up of results. There are no 
specific plans to disseminate the results of the research 
to study participants or the relevant patient community 
beyond the usual channels of publication.
role of the funding source
The study sponsor (Menarini Group) contributed to the 
study design, data analysis and manuscript preparation. MH 
confirms that he had full access to all the data in the study 
and had final responsibility for the decision to submit for 
publication.
results
Of the 792 patients screened, 654 were randomised and 
received study treatment, one patient was excluded from 
any analysis being <18 years old (figure 1, table 1).
Table 6 Summary of Patient Global Evaluation scores 
measured on a 5-point VRS (1=poor to 5=excellent) at the 
end of assessment period (ITT population)
Value
TRAM/DKP
n=260
TRAM/
paracetamol 
n=262
Placebo
n=131
Score (n, %)
  Poor 17 (6.5) 61 (23.3) 91 (69.5)
  Fair 26 (10.0) 40 (15.3) 18 (13.7)
  Good 54 (20.8) 55 (21) 14 (10.7)
  Very good 100 (38.5) 62 (23.7) 4 (3.1)
  Excellent 56 (21.5) 31 (11.8) 2 (1.5)
  Not assessed 7 (2.7) 13 (5.0) 2 (1.5)
  Mean score (SD)* 3.6 (1.14) 2.8 (1.37) 1.5 (0.92)
*Statistical test TRAM/paracetamol versus TRAM/DKP (p<0.0001).
ITT, intention to treat; TRAM/DKP, tramadol/dexketoprofen; VRS, 
Verbal Rating Scale. 
Figure 8 Kaplan-Meier estimation of time to patient report of confirmed first perceptible pain relief (FPPAR) represents the 
cumulative percentage of patients reporting confirmed FPPAR over the time (in minutes) in the TRAM/DKP arm and TRAM/
paracetamol arm. TRAM/DKP, tramadol/dexketoprofen.
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The safety population comprised 653 patients as did 
the ITT group. Patients were enrolled at hospital clinics 
and dental surgeries across five European countries (66 
patients in Hungary, 180 in Italy, 127 in Poland, 141 in 
Spain and 139 in the UK).
Efficacy analyses for non-inferiority were performed 
on the PP population, including a total of 620 
randomised patients as 33 participants were excluded 
due to major protocol deviations related to efficacy 
endpoints of primary interest. Patients’ assignment to 
the different analysis populations occurred before the 
study blind was broken. One patient in the TRAM/
paracetamol arm was lost at follow-up and did not 
Figure 10 Mean scores of patients’ global evaluation by 
treatment arm assessed on 5-point Verbal Rating Scale 
(1=poor to 5=excellent). *Statistically significant TRAM/DKP 
versus TRAM/paracetamol (p<0.0001). TRAM/DKP, tramadol/
dexketoprofen. 
Figure 11 Percentage of subjects who rated the treatment 
as poor, fair, good, very good or excellent on patients’ 
global evaluation by treatment arm. TRAM/DKP, tramadol/
dexketoprofen.
Figure 9 Kaplan-Meier estimation of time to patient report of meaningful pain relief (MPAR) represents the cumulative 
percentage of patients reporting MPAR over the time (in minutes) in the TRAM/DKP arm and TRAM/paracetamol arm. TRAM/
DKP, tramadol/dexketoprofen.
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attend end of study visit (figure 1). Demography and 
baseline characteristics of different treatment groups 
were comparable (table 2).
The mean (SD) age was 26.8 (7.48) years (range 
18–52) in TRAM/DKP, 27.1 (8.13) years (range 18–63) in 
TRAM/Paracetamol; 26.5 (7.67) years (18–59) in placebo 
arm. Percentages of women were 58.5% in TRAM/DKP, 
60.3% in TRAM/Paracetamol and 59.5% in placebo arm 
(table 2). Patients reported mean (SD) PI values at base-
line of 5.7 (1.36); 5.5 (1.34) and 5.6 (1.30) in the TRAM/
DKP, TRAM/paracetamol and placebo arm, respectively 
(table 2).
Figure 12 Percentage of patient taking first rescue medication within 2, 4, 6 and 8 hours after drug intake. * Statistically 
significant TRAM/DKP versus TRAM/paracetamol (p<0.01). TRAM/DKP, tramadol/dexketoprofen.
Figure 13 Kaplan-Meier estimation of time to RM intake represents the cumulative percentage of patients using RM over 
the time (in minutes) in the TRAM/DKP arm and TRAM/paracetamol arm. RM, rescue medication; TRAM/DKP, tramadol/
dexketoprofen. 
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effICACy results
Primary endpoint
Overall, the combination TRAM/DKP showed the 
greatest sustained analgesia during the 6-hour post-
dose period as demonstrated by the TOTPAR6 primary 
endpoint, compared with the TRAM/paracetamol and 
placebo groups. Since non-inferiority was confirmed, the 
ITT population was used to perform superiority analyses 
on the primary endpoint, as prespecified. The mean 
(SD) TOTPAR6 reported by patients in the TRAM/DKP 
group was 13 (7.0), while those in TRAM/paracetamol 
and placebo groups were 9.2 (7.7) and 1.9 (3.9), respec-
tively, demonstrating that the combination TRAM/DKP 
was statistically superior (p<0.0001) to TRAM/parac-
etamol (table 3 and figure 2). The results of the analysis 
conducted on ITT population were consistent with those 
conducted on the PP, therefore, the model sensitivity was 
confirmed.
secondary endpoints
The time course of the mean PAR and PI scores showed 
that TRAM/DKP provided a more rapid onset of action 
compared with TRAM/paracetamol as differences were 
statistically significant already 30 min postdose. Further-
more, patients in the TRAM/DKP arm constantly had 
greater analgesia and lower PI, in a statistically and clini-
cally significant fashion, at each prespecified time points 
until 6 hours after drug intake, in comparison to those in 
the comparator arm (figures 3 and 4). In addition, the PI 
analysis with repeated measures indicated superiority of 
the combination TRAM/DKP in comparison to TRAM/
paracetamol during the overall 8-hour period of assess-
ment (p=0.0009). The superiority of TRAM/DKP was also 
confirmed by mean values of the main secondary efficacy 
variable SPID6 (table 3). Analysis of summary efficacy 
measures including TOTPAR2, 4 and 8; SPID2, 4 and 8; 
% max TOTPAR over 2, 4, 6 and 8 hours; % max SPID 
over 2, 4, 6 and 8 hours provided further confirmation 
of the superiority of TRAM/DKP versus TRAM/parac-
etamol (p<0.0001) (table 3, figures 2 and 5). Regarding 
percentage of responders (patients achieving at least 
50% of maxTOTPAR), the best results were detected in 
patients treated with TRAM/DKP, who were considered 
responders: 71.2%, 2 hours and at 4 hours, 60.4% at 
6 hours and 47.7% at 8 hours. While responders in the 
TRAM/paracetamol group were 44.3%, 43.1%, 38.5% 
and 35.5% at 2, 4, 6 and 8 hours, respectively (p<0.01 for 
each time point) (table 4). In addition, when responders 
were defined as subjects who achieved at least 30% of PI 
reduction versus baseline, the best results were observed 
with TRAM/DKP versus TRAM/paracetamol at 2, 4 and 
6 hours (p<0.01) (table 4, figure 6).
The onset of analgesia, evaluated with the double stop-
watch method, was significantly faster in the TRAM/
DKP group in comparison to TRAM/paracetamol group 
considering all the relevant secondary endpoints (FPPAR, 
confirmed FPPAR and MPAR) measured within different 
time periods (30 min, 1 hour and 2 hours postdose). 
Significantly more patients in the TRAM/DKP group 
reported a confirmed FPPAR compared with patients in 
the TRAM/paracetamol group: 76.9% vs 60.3% at 30 min, 
90.0% vs 72.5% at 1 hour, and 90.4% vs 72.9% at 2 hours 
(p<0.0001) (table 5, figure 7).
The median (95% CI) times to confirmed FPPAR and 
MPAR after single dose of TRAM/DKP were 22 (18 to 
24) and 42 (33 to 45) min, respectively; while the ones 
in the TRAM/paracetamol group were 27 (23 to 27) and 
57 (49 to 57) min, respectively. Log-rank test between 
TRAM/DKP and active comparator showed a statistically 
significant difference (p<0.0001) (figures 8 and 9). PGE 
data also showed a better performance of the combina-
tion containing DKP and TRAM over the comparator. 
Significantly more patients in TRAM/DKP arm (80.8%) 
rated the study medication as ‘good’, ‘very good’ or 
‘excellent’, than that in the TRAM/paracetamol (56.6%) 
and placebo (15.3%) groups (table 6, figures 10 and 11).
RM was required by significantly fewer patients in the 
TRAM/DKP group (7.7% within 2 hours; 14.6% within 
4 hours; 33.8% within 6 hours) than in the TRAM/
paracetamol group (20.6% within 2 hours; 36.3% within 
4 hours; 45.8% within 6 hours) (p<0.01). The majority of 
patients randomised to placebo took RM (73.3% within 
2 hours; 82.4% within 4 hours; 87.8% within 6 hours). 
Patients in TRAM/paracetamol group used RM more 
quickly than patients in TRAM/DKP group (p=0.0373) 
(figures 12 and 13).
safety
Overall, 53 patients (8.1%) experienced one or more 
adverse drug reactions (97 ADRs in total) but none of the 
ADRs were considered to be serious (table 7).
No clinically relevant differences were identified in 
ADRs incidences between treatment groups. Overall, 
the most common ADRs were: vomiting (3.8%), nausea 
(3.4%), dizziness (2.9%) and somnolence (2.1%) 
(table 8). No deaths or other significant ADRs occurred. 
There were no clinically relevant changes in the VSs or 
physical examination versus baseline. Overall, TRAM/
Table 7 Overview of ADRs, by treatment and overall
TRAM/
DKP 
n=260, (%)
TRAM/
paracetamol
n=262, (%)
Placebo
n=131, (%)
Overall
n=653, (%)
Overall 43/22 (8.5) 52/29 (11.1) 2/2 (1.5) 97/53 (8.1)
Intensity
  Mild 21/13 (5.0) 26/17 (6.5) 2/2 (1.5) 49/32 (4.9)
  Moderate 16/7 (2.7) 24/16 (6.1) 0/0 (0.0) 40/23 (3.5)
  Severe 6/3 (1.2) 2/2 (0.8) 0/0 (0.0) 8/5 (0.8)
Serious ADR 0/0 (0.0) 0/0 (0.0) 0/0 (0.0) 0/0 (0.0)
Results expressed as number of events/number of patients (%) 
(safety population).
 Percentages calculated considering the number of patients in the 
relative treatment group.
ADRs, adverse drug reactions; TRAM/DKP, tramadol/
dexketoprofen.
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DKP was safe and well tolerated, presenting a safety and 
tolerability profile fully in line with that observed in 
previous clinical experience.
DIsCussIOn
This study shows that TRAM/DKP provides an effective 
analgesia for the control of moderate to severe pain 
following removal of impacted lower third molar and is 
superior to TRAM/paracetamol in terms of rapidity of 
onset and intensity of analgesia. Statistically and clinically 
significant superiority of TRAM/DKP over TRAM/parac-
etamol was demonstrated with an overall consistency not 
only at the primary endpoint (ie, TOTPAR6), but also 
at all different outcome measures adopted in the study. 
Study participants receiving TRAM/DKP combination 
reported lower pain scores already at the 30 min time 
point after drug administration.
limitations
The main limitation is that this was a single-dose study and 
as such assessed only the short-term analgesic efficacy of 
TRAM/DKP in comparison with TRAM/paracetamol. In 
addition, although it has been proposed that systematic 
differences in the estimate of analgesic efficacy between 
dental and postsurgical pain models are unlikely,26 and 
efficacy in the dental model is highly predictive of effi-
cacy in later stage models in drug development,12 further 
studies with similar design applied in other acute pain 
conditions are warranted.
Generalisability
The results of this head-to-head trial can guide physicians 
in choosing the adequate analgesic medication to opti-
mise clinical outcomes in the treatment of a wide range of 
acute pain. This is particularly true in a moment in which 
there is a clear tendency to abandon the early treatment 
Table 8 Overview of adverse drug reactions by MedDRA system organ class (SOC) and preferred term (PT)
SOC/PT TRAM/DKP n=260, (%)
TRAM/paracetamol 
n=262, (%) Placebo n=131, (%) Overall n=653, (%)
Overall 43/22 (8.5) 52/29 (11.1) 2/2 (1.5) 97/53 (8.1)
Cardiac disorders
  Overall 0/0 (0.0) 1/1 (0.4) 0/0 (0.0) 1/1 (0.2)
  Palpitations 0/0 (0.0) 1/1 (0.4) 0/0 (0.0) 1/1 (0.2)
Gastrointestinal disorders 
  Overall 22/16 (6.2) 27/21 (8.0) 0/0 (0.0) 49/37 (5.7) 
  Abdominal discomfort 1/1 (0.4) 0/0 (0.0) 0/0 (0.0) 1/1 (0.2)
  Diarrhoea 0/0 (0.0) 1/1 (0.4) 0/0 (0.0) 1/1 (0.2)
  Nausea 10/10 (3.9) 12/12 (4.6) 0/0 (0.0) 22/22 (3.4)
  Vomiting 11/11 (4.2) 14/14 (5.3) 0/0 (0.0) 25/25 (3.8)
General disorders and administration site conditions
  Overall 4/3 (1.2) 2/2 (0.8) 0/0 (0.0) 6/5 (0.8)
  Asthenia 1/1 (0.4) 1/1 (0.4) 0/0 (0.0) 2/2 (0.3)
  Fatigue 0/0 (0.0) 1/1 (0.4) 0/0 (0.0) 1/1 (0.2)
  Malaise 3/3 (1.2) 0/0 (0.0) 0/0 (0.0) 3/3 (0.5)
Nervous system disorders
  Overall 17/14 (5.4) 21/17 (6.5) 2/2 (1.5) 40/33 (5.1)
  Amnesia 1/1 (0.4) 0/0 (0.0) 0/0 (0.0) 1/1 (0.2)
  Dizziness 6/6 (2.3) 13/13 (5.0) 0/0 (0.0) 19/19 (2.9)
  Headache 2/2 (0.8) 1/1 (0.4) 1/1 (0.8) 4/4 (0.6)
  Presyncope 0/0 (0.0) 1/1 (0.4) 0/0 (0.0) 1/1 (0.2)
  Somnolence 8/8 (3.1) 5/5 (1.9) 1/1 (0.8) 14/14 (2.1)
  Tremor 0/0 (0.0) 1/1 (0.4) 0/0 (0.0) 1/1 (0.2)
Vascular disorders
  Overall 0/0 (0.0) 1/1 (0.4) 0/0 (0.0) 1/1 (0.2)
  Hypotension 0/0 (0.0) 1/1 (0.4) 0/0 (0.0) 1/1 (0.2)
TRAM/DKP, tramadol/dexketoprofen. 
Results are expressed as number of events/number of patients (%) (safety population).
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with strong opioids, in patients suffering from acute 
moderate to severe pain. Results of the present trial rein-
force the clinical benefit of TRAM/DKP that emerged 
in the whole developmental clinical programme of this 
fixed combination that involved some 1900 patients with 
moderate to severe acute pain assessed using well-es-
tablished human models of acute visceral and somatic 
moderate to severe pain.11–16
Interpretation
Fast action is an important feature for an analgesic 
intended to be used in the treatment of acute pain.29 
The earlier onset of analgesic efficacy with TRAM/
DKP compared with TRAM/paracetamol may be attrib-
utable to the rapid and high bioavailability of DKP,29 30 
that favours the rapid onset of action of the combina-
tion. Better analgesic efficacy was maintained consis-
tently over the entire observation period, confirming the 
sustained analgesic action observed in previous clinical 
trials assessing efficacy following third molar extraction, 
abdominal hysterectomy and total hip arthroplasty.11 13 14 
The greater analgesic efficacy of TRAM/DKP results from 
the balanced and synergistic combination of peripheral 
and central analgesia, complemented with an anti-inflam-
matory action.13 The combination TRAM/paracetamol 
is substantially lacking in anti-inflammatory activity, as 
paracetamol only inhibits the synthesis of prostaglandins 
in the central nervous system and peripherally blocks 
pain impulse generation, but unlike NSAIDs, is not a 
peripheral COX inhibitor.31 32 It can be hypothesised that 
this difference could have contributed to the observed 
reduced analgesic efficacy.
The two combinations showed clinically comparable 
safety profiles. Gastrointestinal disorders including 
abdominal discomfort, diarrhoea, nausea and vomiting 
were reported with similar frequencies between the two 
groups of patients who received active intervention. 
Adverse reactions regarding the nervous system disorders 
were also observed in a similar proportion in both arms, 
although a trend towards improved tolerability could be 
detected in patients receiving TRAM/DKP, as compared 
with patients treated with TRAM/paracetamol.
COnClusIOn
This study has confirmed that TRAM hydrochloride/
DKP trometamol 75/25 mg oral fixed combination is 
effective and superior over TRAM hydrochloride/parac-
etamol 75/650 mg in relieving moderate to severe acute 
pain following removal of impacted lower third molar. 
TRAM hydrochloride/DKP trometamol 75/25 mg oral 
fixed combination shows faster onset of effect, greater 
and durable analgesia, together with a favourable safety 
profile. The rapid onset of analgesic effect of DKP, with 
its anti-inflammatory activity, associated to the sustained 
action of TRAM, makes this combination a valuable tool 
to achieve multimodal analgesia.
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